跳至主導覽 跳至搜尋 跳過主要內容

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan

  • Shih Lung Cheng
  • , Chau Chyun Sheu
  • , Chih Feng Chian
  • , Jeng Yuan Hsu
  • , Kuo Chin Kao
  • , Liang Wen Hang
  • , Ching Hsiung Lin
  • , Wen Feng Fang
  • , Hao Chien Wang*
  • , Diahn Warng Perng*
  • *此作品的通信作者
  • Yuan Ze University
  • Far Eastern Memorial Hospital
  • Kaohsiung Medical University
  • Triservice General Hospital Taiwan
  • Veterans General Hospital-Taichung Taiwan
  • China Medical University Taichung
  • National Chung Hsing University
  • MingDao University
  • Changhua Christian Hospital
  • Chang Gung University
  • National Taiwan University
  • National Yang Ming Chiao Tung University

研究成果: 期刊稿件 › 文章 › 同儕審查

6 引文 斯高帕斯(Scopus)

摘要

Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 patients (aged 74.6 ± 9.1 years and 83.2% men) with IPF were collected over 2 years (2018−2020) from medical centers in Taiwan at baseline, 1 month, and subsequent 3-month intervals. Treated patients (n = 88) received the antifibrotics nintedanib or pirfenidone, compared with the untreated group (n = 13). The 2-year assessment revealed overall preserved lung functionality in the treated patients, with insignificant changes from baseline for percent predicted forced vital capacity or FVC (±1.7%). The presence of respiratory comorbidities significantly increased the risk of both AE and death (with or without AE) over the full study duration. Furthermore, the decline of predicted FVC significantly increased with the risk of acute exacerbations (AE) in the second year. Overall, antifibrotic medication was beneficial in stalling IPF progression, reducing AEs, and delaying mortality in the treated cohort, despite their lower baseline lung functions. Further, no new safety concerns over antifibrotic treatments were observed for the Taiwanese population.

原文英語
文章編號2362
期刊Biomedicines
卷10
發行號10
DOIs
出版品狀態已出版 - 10 2022

文獻附註

Publisher Copyright:
© 2022 by the authors.

指紋

深入研究「NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan」主題。共同形成了獨特的指紋。

引用此